Verdiva Bio discontinues Phase 2 trial of oral GLP-1 drug VRB-101 for obesity maintenance
Verdiva Bio has terminated its Phase 2 study testing VRB-101, an oral formulation of the GLP-1 drug ecnoglutide, as a maintenance treatment for patients with overweight and obesity. The company cited 'market evolution' as the reason for the business decision, which was not based on safety concerns, though it will continue developing the drug for other weight loss indications.
2 sourcesWeight management
00